Akèy › Kansè fwa (Kasinòm epatoselilè) › Pennsylvania
Etid klinik pou Kansè fwa (Kasinòm epatoselilè) nan Pennsylvania
27 etid pou Kansè fwa (Kasinòm epatoselilè) ap chèche patisipan nan sit nan Pennsylvania.
Vil nan Pennsylvania
Tèks ofisyèl etid la (Anglè)
A Phase 1 Study of the Safety and Tolerability of CTX-10726
- UPMC Hillman Cancer Center, Pittsburgh
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07419841Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #104, Hershey
- Exelixis Clinical Site #98, Philadelphia
- Exelixis Clinical Site #32, Pittsburgh
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT05176483National Liver Cancer Screening Trial
- University of Pennsylvania, Philadelphia
Ap rekriteFaz 4
Laj 18 a 85 · Tout sèks · Mizajou Sep 25, 2026 · NCT06084234A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT06427941Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
- Lehigh Valley Hospital, Allentown
Ap rekriteEtid obsèvasyon
Laj 22 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06486454Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
- UPMC Hillman Cancer Center, Pittsburgh
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06811116Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, Philadelphia
- Research Site, Pittsburgh
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06921785Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Ap rekriteFaz 1/2
12 Months – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT04851119FOG-001 in Locally Advanced or Metastatic Solid Tumors
- University of Pennsylvania, Perelman School of Medicine, Philadelphia
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05919264Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- Christiana Care Health System-Concord Health Center, Chadds Ford
- Geisinger Medical Center, Danville
- Geisinger Cancer Center Dickson City, Dickson City
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT07166406Molecular Basis of Pediatric Liver Cancer
- UPMC Children's Hospital of Pittsburgh, Pittsburgh
Ap rekriteEtid obsèvasyon
Laj 0 a 99 · Tout sèks · Mizajou Aug 10, 2026 · NCT03959800Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
- Allegheny General Hospital, Pittsburgh
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT05168163A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Thomas Jefferson University, Philadelphia
Ap rekriteFaz 2
Laj 8 ak plis · Tout sèks · Mizajou Jul 27, 2026 · NCT05503797Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
- UPMC Hillman Cancer Center, Pittsburgh
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 23, 2026 · NCT04114136A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Clinical Trial Site, Pittsburgh
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 17, 2026 · NCT06600321Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia
Ap rekrite
Laj 18 a 75 · Tout sèks · Mizajou Jun 17, 2026 · NCT05486572Y-90 Treatment Response Using Transarterial Radioembolization
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 10, 2026 · NCT07145801Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
- University of Pennsylvania, Philadelphia
Ap rekriteFaz 1/2
Laj 20 a 99 · Tout sèks · Mizajou Apr 20, 2026 · NCT02174549Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
- UPMC Hillman Cancer Center, Pittsburgh
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 16, 2026 · NCT07223424Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 16, 2026 · NCT05842174Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 2, 2026 · NCT05733598SBRT With Atezo/Bev for HCC
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Ap rekriteFaz 1
Laj 18 a 99 · Tout sèks · Mizajou Feb 20, 2026 · NCT05488522Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients
- Thomas Jefferson Hospital, Philadelphia
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jan 26, 2026 · NCT05705219Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- Penn State Hershey Medical Center, Hershey
- Albert Einstein Healthcare Network, Philadelphia
Ap rekriteFaz 4
Laj 18 a 64 · Tout sèks · Mizajou Jan 22, 2026 · NCT04373564Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- UPMC Hillman Cancer Center, Pittsburgh
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jan 21, 2026 · NCT03539822Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
- UPMC Hillman Cancer Center, Pittsburgh
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Nov 6, 2025 · NCT06698250SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Philadelphia
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.